Fetoscopic Endoluminal Tracheal Occlusion (FETO) Trial – Congenital Diaphragmatic Hernia
Lead Physician: Anthony Johnson, DO
In an effort to improve outcomes in babies affected with Congenital Diaphragmatic Hernia (CDH), The Fetal Center recently obtained FDA approval to conduct a feasibility study of fetoscopic endoluminal tracheal occlusion (FETO) in eligible patients, reserved for the most severe CDH cases who may not otherwise survive past delivery. The FETO trial is a multi-center study aimed to determine whether fetal endoscopic tracheal occlusion (FETO) improves survival in cases of severe isolated CDH.
See full study details at clinicaltrials.gov/show/NCT02596802
The affiliated multidisciplinary team at The Fetal Center at Children’s Memorial Hermann Hospital works closely with referring physicians and patients to identify eligible candidates for the study. This includes:
- Mothers between the ages 18 – 50 years with a singleton pregnancy
- Isolated left-sided diaphragmatic hernia with liver herniation into chest (“liver up”)
- Severe pulmonary hypoplasia with Observed to Expected Lung-Head Ratio (O/E LHR) <30%
- Normal chromosomes
- Family must be willing to live within 30 minutes of Children’s Memorial Hermann Hospital while the balloon remains in the fetus.
The balloon is placed at 270 to 316 weeks gestation and is removed between 340 and 346 weeks gestation due to the risk of rupture of the membranes and premature labor. Comprehensive evaluation is essential to determine whether patient is a candidate for prenatal repair.
To refer a patient to The Fetal Center for evaluation for participation in the FETO trial or if you have any questions, call (832) 325-7288 or email us at email@example.com.
See more info on how CDH is treated here at Children's Memorial Hermann Hospital »